Ikarian Capital’s GeneDx Holdings WGS Stock Holding History

Ikarian Capital’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,061	Closed	-$2.8M	–	256
2021 Q2	$2.8M	Buy	+6,061	New	+$2.6M	0.23%	104

Other funds holding WGS

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ikarian Capital's WGS Position: Q3 2021 in Review

Ikarian Capital sold out of GeneDx Holdings (WGS) in Q3 2021, closing a stake of 6,061 shares — an estimated $2.8M sold.

Ikarian Capital first reported a position in WGS in Q2 2021 and held it in 1 quarter. The position peaked at $2.8M in Q2 2021. 86 funds tracked by Wall St. Rank hold WGS as of Q3 2021.

Ikarian Capital reported no remaining GeneDx Holdings position as of Q3 2021 after selling out during the quarter.
Ikarian Capital sold 6,061 GeneDx Holdings shares in Q3 2021, an estimated $2.8M.
Ikarian Capital first reported a position in GeneDx Holdings in Q2 2021 and held it in 1 quarter.
Ikarian Capital's GeneDx Holdings position peaked at $2.8M in Q2 2021.
86 funds tracked by Wall St. Rank held GeneDx Holdings as of Q3 2021.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.